Table 3.
Comparison clinical outcomes between DLBCL patients with and without HBsAg-seropositive
| Clinical factors | Studies | Total | Effect Estimate | p value | |
|---|---|---|---|---|---|
| Prognosis (figure 2) | Two-year OS (A) | 7 | 1469 | 1.54[1.23,1.92] * | <0.001 |
| Five-year OS (B) | 8 | 1756 | 1.79[1.48,2.17] * | <0.001 | |
| Two-year PFS (C) | 4 | 1069 | 1.44[1.14,1.81] * | 0.002 | |
| Five-year PFS (D) | 3 | 834 | 1.34[1.02,1.75] * | 0.03 | |
| Response to chemotherapy (figure 3) | CR (A) | 10 | 2389 | 0.48[0.34,0.68] | <0.001 |
| PD (B) | 7 | 1986 | 2.08[1.34.3.24] | 0.001 | |
| Clinical features (figure 4) | Diagnosed Younger than 60 (A) | 10 | 2585 | 2.19[1.75,2.74] | <0.001 |
| Stage 3 or 4 (B) | 12 | 3150 | 1.85[1.55,2.23] | <0.001 | |
| LDH Level Elevation (C) | 9 | 2200 | 1.40[1.14,1.73] | 0.002 | |
| B Symptoms (D) | 4 | 1159 | 1.31[0.71,2.42] | 0.39 | |
| IPI Score over 2 | 8 | 2037 | 0.93[0.62,1.41] | 0.74 | |
| Extra-nodal sites ≥ 2 (F) | 8 | 2028 | 1.13[0.88, 1.44] | 0.34 | |
| Non-GCB vs. GCB (G) | 5 | 1018 | 0.94[0.48,1.83] | 0.85 | |
* The result is estimated by Hazard ratio.